Here’s a startling fact: obesity isn’t just a health concern—it’s a significant risk factor for breast cancer development and recurrence. But what if a treatment designed for weight management could also play a role in cancer care? That’s the intriguing question at the heart of a groundbreaking study presented at the 2025 San Antonio Breast Cancer Symposium (SABCS). Researchers dove into the real-world use of glucagon-like peptide 1 (GLP-1) receptor agonists among breast cancer patients, exploring their potential impact on clinical outcomes, social determinants of health (SDOH), and even circulating tumor DNA (ctDNA) results. And this is the part most people miss: the findings suggest GLP-1 therapies might do more than just help with weight loss—they could be a game-changer in oncology.
The study, one of the largest of its kind, analyzed electronic health records from a staggering 708,406 breast cancer patients diagnosed between January 2011 and February 2025. Using AI-powered data extraction, researchers examined who was using GLP-1 medications, why they were using them, and how this correlated with ctDNA testing and tumor activity. But here’s where it gets controversial: while GLP-1 use was linked to lower ctDNA positivity, suggesting reduced tumor activity, the study also uncovered disparities in access to these therapies, raising questions about equity in cancer care.
So, who’s actually using GLP-1? Turns out, it’s primarily patients with a body mass index of 30 or higher, non-Latinx Black individuals, and those in rural areas or using telemedicine. Interestingly, usage was lower among older patients, those with advanced-stage cancer, Latinx and Asian patients, and individuals with limited English proficiency. These patterns highlight not just clinical needs but also societal barriers to care.
Here’s the kicker: GLP-1 users were more likely to undergo ctDNA testing (2.8% vs. 1.5%) and had lower ctDNA positivity rates (25.8% vs. 31.6%). This hints at a potential link between GLP-1 therapy and reduced tumor activity, though the exact mechanisms remain unclear. Could these medications be doing more than managing weight? Researchers are calling for further studies to explore whether GLP-1 drugs directly influence breast cancer outcomes and to address disparities in access.
This study isn’t just about numbers—it’s about possibilities. By shedding light on the intersection of weight management, oncology, and social determinants of health, it opens doors for future research and more equitable care. But we have to ask: Are we doing enough to ensure all patients benefit from these therapies? Share your thoughts in the comments—let’s keep the conversation going.
